ESMO Media Releases

At the 71st World Health Assembly (WHA) in Geneva, Switzerland, ESMO, the leading professional organisation for medical oncology, delivered two statements positioning cancer as a priority on the World Health Organisation’s (WHO) global agenda.

ESMO, the leading professional organisation for medical oncology, shares concerns expressed in a scientific paper and reflected in the international media about the rising costs of cancer medicines.

Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life.

Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

ESMO welcomes the latest reports from The Cancer Genome Atlas (TCGA) as a major resource for researchers across the world and calls for increased across-the-board commitment to translate these efforts into medical advances for the benefit of cancer patients.

The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi.

Around  2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research in the field of lung cancer.

The decline in cancer of the intestines – colorectal cancer – is one of the major success stories of the past 30 years in Europe say researchers, as they predict that in 2018 death rates from the disease will continue to fall by around seven per cent compared to 2012.

New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to data presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

”Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

The TAT (Targeted Anticancer Therapies) International Congress 2018 will take place in Paris, France where around 450 attendees from all over the world are expected to join what is renowned to be “the home of phase I in oncology.”